Research programme: immunomodulators - Cytune Pharma/SOTIO

Drug Profile

Research programme: immunomodulators - Cytune Pharma/SOTIO

Alternative Names: CYP 0150; CYP 0150 (RLI); IL-15-IL-15 receptor α fusion protein; Interleukin-15-interleukin-15 receptor alpha fusion protein; RLI; RLI 15; SO C101; Super IL-15 cytokine

Latest Information Update: 01 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cytune Pharma
  • Developer Cytune Pharma; SOTIO
  • Class Antineoplastics; Recombinant proteins
  • Mechanism of Action Immunostimulants; Interleukin-15 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer; Colorectal cancer; Malignant melanoma

Most Recent Events

  • 28 Nov 2017 Preclinical development is ongoing in France (9227911; Cytune Pharma pipeline, November 2017)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in France (Parenteral, Injection)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Colorectal-cancer in France (Parenteral, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top